Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases

References

• Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort – an epi-IBD study. J Crohn’s Colitis. 2019;13:198–208.
   Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an epi-IBD study. Gut. 2019;68(3):423–433.
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337.
   PubMed Web of Science ®Google Scholar
• Hoivik ML, Moum B, Solberg IC, et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis. 2012;18(8):1540–1549.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn’s Colitis. 2017;11(7):769–784.
   Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
   PubMed Web of Science ®Google Scholar
• Davies SC, Nguyen TM, Parker CE, et al. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2019;12:CD012804.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6(4):567–572.
   PubMed Web of Science ®Google Scholar
• Entyvio (vedolizumab). Summary of product characteristics. Takeda Pharma A/S; 2018. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiFtJKklJjtAhUFC-wKHa-ZCxYQFjAAegQIBBAC&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Fentyvio-epar-product-information_en.pdf&usg=AOvVaw2dLpRo7terlKFQG (accessed 23 November 2020).
   Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Dulai P, Meserve J, Hartke J, et al. DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium. J Crohn’s Colitis. 2017;11(suppl_1):S40–S41.
   Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Verstockt B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease-a multicenter retrospective European study. Inflamm Bowel Dis. 2018;24(11):2442–2451.
   PubMed Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113(9):1345.
   Web of Science ®Google Scholar
• Feagan BG, Lasch K, Lissoos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130–138.e7.
   PubMed Web of Science ®Google Scholar
• Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019;14(4):e0215491.
   PubMed Web of Science ®Google Scholar
• Plevris N, Chuah CS, Allen RM, et al. Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort. J Crohns Colitis. 2019;13(9):1111–1120.
   PubMed Web of Science ®Google Scholar
• Danese S, Sandborn WJ, Colombel J-F, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. Gastroenterology. 2019;157(4):1007–1018.e7.
   PubMed Web of Science ®Google Scholar
• Pulusu SSR, Srinivasan A, Krishnaprasad K, et al. Vedolizumab for ulcerative colitis: real world outcomes from a multicenter observational cohort of Australia and Oxford. WJG. 2020;26(30):4428–4441.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Renna S, et al. Effectiveness and safety of vedolizumab in biologically naïve patients: a real-world multi-centre study. United European Gastroenterol J. 2020;8(9):1045–1055.
   PubMed Web of Science ®Google Scholar
• Reenaers C, Cremer A, Dewit O, et al. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease: results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE). Acta Gastroenterol Belg. 2020;83(1):15–23.
   PubMed Web of Science ®Google Scholar
• Helwig U, Mross M, Schubert S, et al. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. BMC Gastroenterol. 2020;20(1):211.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis. 2017;11(6):649–670.
   Google Scholar
• Harvey R, Bradshaw J. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514.
   Google Scholar
• Sandborn W, Feagan B, Hanauer S, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122(2):512–530.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
   PubMed Web of Science ®Google Scholar
• Moskovitz D, Daperno M, Van-Assche G. Defining and validating cut-offs for the Simple Endoscopic Score for Crohn’s disease. Gastroenterology. 2007;132:S1097.
   Web of Science ®Google Scholar
• Fescharek R, Kübler J, Elsasser U, et al. Medical dictionary for regulatory activities (MedDRA). Int J Pharm Med. 2004;18:259–269.
   Google Scholar
• Silverberg M, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl a):5A–36A.
   PubMed Web of Science ®Google Scholar
• Vedolizumab for treating moderately to severely active ulcerative colitis. National Institute for Health and Care Excellence: NICE: Technology appraisal guidance [TA342]. 2015
   Google Scholar
• Treatment guidelines including agent recommendation for usage of expensive medicines in the treatment of inflammatory bowel diseases. Medicinrådet. Available from: https://medicinraadet.dk/arkiv/laegemiddelrekommandationer/mave-og-tarmsygdomme/kroniske-inflammatoriske-tarmsygdomme/kroniske-inflammatoriske-tarmsygdomme-3-6-rads-arkiv (accessed 21 February 2021).
   Google Scholar
• Cohen NA, Plevris N, Kopylov U, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterol J. 2020;8(9):1076–1085.
   PubMed Web of Science ®Google Scholar
• Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873–879.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064.
   PubMed Web of Science ®Google Scholar
• Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442–1447.
   PubMed Web of Science ®Google Scholar
• Ma C, Beilman CL, Huang VW, et al. Anti-TNF therapy within 2 years of Crohn’s disease diagnosis improves patient outcomes: a retrospective cohort study. Inflamm Bowel Dis. 2016;22(4):870–879.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851.
   PubMed Web of Science ®Google Scholar